Olympus-backed PAI Pharma acquires Nexus Pharmaceuticals
Nexus Pharmaceuticals, a U.S. specialty pharmaceutical company making complex injectable medicines, adds more than 20 hospital injectable products to PAI Pharma.
Nexus is a U.S.-based specialty pharmaceutical company focused on developing and commercializing complex injectable medicines used in critical care, oncology and other hospital settings. Its portfolio includes therapies that have historically faced supply shortages, and it works with contract manufacturing partners across the U.S. hospital market.
PAI said the deal strengthens its ability to serve hospitals with a broader range of pharmaceutical products, building on its recent acquisition of Nivagen and its aseptic manufacturing capabilities in Sacramento. William Blair acted as exclusive adviser to PAI Pharma, with Kirkland & Ellis LLP as its legal counsel; Proskauer Rose LLP advised Nexus.
Deal facts
- Target
- Nexus Pharmaceuticals
- Business
- U.S. specialty pharmaceutical company developing and commercializing complex injectable medicines for critical care, oncology and hospital settings
- Acquirer
- PAI Pharma
- Backed by
- Olympus Partners
- Deal type
- Add-on
- Advisers
- William Blair financial adviser to PAI Pharma
- Kirkland & Ellis LLP legal counsel to PAI Pharma
- Proskauer Rose LLP legal counsel to Nexus Pharmaceuticals
- Status
- Completed
- Announced
- Thursday, November 12, 2026
Sources
- PR NewswireNov 12, 2026
- Yahoo FinanceNov 12, 2026
Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.